📰 MIRM: FDA Approves Mirum's Atebrioz for FOP, First Drug to Reduce New Bone Growth

News: BusinessWire

Ticker: MIRM | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

The FDA approved Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva (FOP), a devastating ultra-rare disease affecting ~300 U.S. patients. This is the first therapy shown to reduce new heterotopic ossification volume—the hallmark of FOP—with a 3.2 cm3 decrease vs a 24.6 cm3 increase on placebo at 24 weeks. Mirum licensed the drug from Incyte and will commercialize it in the U.S. starting October 2026, with a patient support program offering $0 copay for eligible patients. Incyte received a Rare Pediatric Disease Priority Review Voucher, a valuable asset. The approval validates Mirum's rare disease strategy and adds a second commercial product to its portfolio, following LIVMARLI. An EMA decision is pending, and pediatric cohorts are enrolling to expand the label to younger children.

Further Research: 🤖 Wiseek AI Analysis | 📰 Original Article

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.